Scotland Fails To Recommend Orkambi But 'New Medicines Fund' Should Enable Access
Executive Summary
The Scottish Medicines Consortium (SMC) on May 9 published advice mirroring that of its neighbor NICE failing to recommend the use of Vertex's Orkambi on the UK's NHS for the treatment of cystic fibrosis. This comes despite positive reimbursement decisions in other European countries. However, Scotland's New Medicines Fund should ensure there is a route available for patients to access the medicine, Vertex believes.
You may also be interested in...
Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi
The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.
'No Surprise' Says Vertex As NICE Fails To Recommend Orkambi In CF
Vertex Pharmaceuticals Inc. says it is "not surprised" that NICE has issued draft guidance not recommending Orkambi (lumacaftor/ivacaftor) for use on the NHS in England.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.